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diabetic chronic treatments (40% for both), and 27% were on insulin therapy.
The other antidiabetic medications, including glinide, glitazone, and acarbose
were rarely used (3%, 2%, and 5%, respectively). Mean baseline and post PCI
Cr levels were 102±52 and 122±81μmol/L. Rate of CIN was similar in
patients with or without metformin (21 vs 20%, respectively, p= 0.87).
Logistic regression for the risk of CIN taking into account classical risk fac-
tors showed no impact of chronic metformin therapy, even in stratified anal-
ysis in patients with chronic kidney disease. Hospital mortality was similar
between groups (7 vs 6%, respectively, p=0.69). Moreover, no case of lactic
acidosis was reported during the hospital stay.
Conclusion: In this multicentre study reflecting current clinical practice,
metformin treatment prior to primary PCI had no significant impact on CIN.
Larger studies are needed to confirm these findings.
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Aim: To compare cardiovascular (CV) outcomes after contemporary PCI
in patients with vs. without renal failure (RF) according to clinical presenta-
tion (ST-elevated myocardial infarction (STEMI), acute coronary syndrome
(ACS), and stable coronary artery disease (sCAD)).
Methods: Consecutive patients undergoing PCI with stent implantation
were prospectively included from 2007 to 2012. RF was defined by a CrCl
<60ml/min. The primary end-point was all cause-mortality. The secondary
endpoints were MACCE (cardiovascular death, myocardial infarction, stroke,
TLR), TLR (target lesion revascularization), and ARC definite/probable stent
thrombosis (ST) at one year.
Results: Among 5337 patients eligible, 1219 (23%) had PCI for STEMI,
1837 (34%) for ACS and 2281 (43%) for sCAD. There were 1441 (27%)
patients with RF. At one year, patients with RF had increased all-cause mor-
tality rates whatever the indication for PCI (Figure), with a 6 fold higher unad-
justed all-cause mortality rate in STEMI patients (41% vs. 7.5%) and a 3 fold
increase in ACS (19% vs. 6%) and sCAD (10% vs. 3%) patients compared to
noRF patients (p< 0.0001 for all comparisons). MACCE were also higher in
RF patients in each PCI indication (45% vs. 15% in STEMI, 23% vs. 14% in
ACS, and 14% vs. 9% in sCAD, p<0.05 for all). STEMI-noRF patients had
comparable mortality (p=0.209) and MACCE rates (p=0.658) than sCAD-RF
patients. TLR ranged from 5.5% to 7.4%, and definite/probable ST was <2.5%
without any difference in each PCI indication (p>0.05 for both). After multi-
variable analyses, RF was independently associated with an excess of death
with a more than doubled relative risk in STEMI compared to ACS and sCAD
patients (OR 5.3: CI 3.627-7.821 in STEMI vs. 2.1: CI 1.465-3.140 and 2.3:
CI: 1.507-3.469 in ACS and sCAD, respectively, p<0.0001).
Conclusion: RF is a stronger independent predictor of death after PCI in
patients with STEMI compared to patients with ACS and sCAD. CV prog-
nosis of sCAD-RF patients was found to be comparable to that of STEMI-
noRF patients.
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Purpose: Cardiac allograft vasculopathy (CAV) constitues a primary cause
of death after heart transplantation. Bare metal stents (BMS) have been used
for revascularization, but they are associated with a high-risk of restenosis.
Limited data have shown favourable results with percutaneous coronary inter-
ventions (PCI) using drug-eluting stents (DES) in this specific population. Our
study focuses on intra-stent restenosis (ISR) for DES in CAV, on new revas-
cularisation and mortality.
Methods: 97 consecutive heart transplant recipients with successful PCI
were treated with DES (n=106) and BMS (n=25). They were prospectively
followed-up at one year after PCI. An angiographic lesion-based analysis at
12-month follow-up and a patient-based survival analysis were performed.
Results: The lesion-based analysis within 12 months after PCI showed an
ISR rate with BMS of 12% and an ISR rate with DES of 3.8%. The target
lesion revascularization (TLR) was 8% for BMS and 2.8% for DES. However,
the target vessel revascularization was higher (16.5%) and the remote lesion
revascularization was 8.7%, indicating the rapid occurrence of new significant
lesions. Cardiac mortality at one year was 9.7% and extra- cardiac mortality
was 2.9%.
Conclusions: DES are associated with a low rate of TLR and can safely
be used in heart transplant recipients with coronary artery disease. However,
new significant lesions occurred at one year indicating a progression of CAV. 
0207
Outcome of patients after resuscitation from out of hospital cardiac
arrest: the role of percutaneous coronary intervention in Clermont-
Ferrand university hospital
Amina Asadi (1), Nicolas Barber-Chamoux (2), Pascal Motreff (2)
(1) CHU Ibn Rochd, Cardiologie, Casablanca, Maroc – (2) CHU Gabriel
Montpied, Cardiologie, Clermont-Ferrand, France
Backround: The hospital cardiac arrest (ACEH) represent the leading
cause of death worldwide. Despite improvements in their care, the prognosis
of these patients remains very pejorative, including those who have received
initial resuscitation success.The objective of this study was to evaluate the
influence of emergency coronary angiography (CAG) and primary percuta-
neous coronary intervention (PCI) on the outcome of patients survivors after
out-of-hospital cardiac arrest and living in ICU in the Auvergne region namely
coronary angiography.
Methods: During 18 months, a cohort of surviving patients admitted alive
in Aceh and resuscitation was incorporated in the CHU Gabriel Montpied. All
demographics, pre-hospital and hospital were analyzed. The multivariate anal-
ysis of prognostic factors in this cohort used mainly the Cox model.
Results: 54 consecutive patients with out-of-hospital cardiac arrest survi-
vors underwent systematic emergency coronary angiography. Most (65%)
OHCA survivors had angiographic coronary artery disease: occlusion in
23 patients (43%) and significant stenosis in 12 patients (22%). Angioplasty
was attempted in 20 patients and was technically successful in 18. Chest pain
and the presence of ST-segment elevation were poor predictors of acute coro-
nary-artery occlusion. Hospital survival was 48%. By multivariable analysis,
use of PCI was an independent factor of survival (p=0.006). 
Conclusion: Acute coronary-artery occlusion is frequent in survivors of
out-of-hospital cardiac arrest and is predicted poorly by clinical and electro-
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cardiographic findings. Accurate diagnosis by immediate coronary angio-
graphy can be followed in suitable candidates by coronary angioplasty, which
seems to improve survival.
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Background: Stenting options for patients at high risk of bleeding
(elderly, AF, ACS) are sub-optimal. BMS are not as effective as DES in
reducing restenosis but DES require long term DAPT, which increases
bleeding risk. Recent animal studies have demonstrated that the nano PzF sur-
face modified stent (Cobra PzF, CeloNova) is thrombo-resistant, and is asso-
ciated with a rapid reendothelialization.
Method: 100 patients (71 men) with mean age 71.4±2 year old of all
comer patients were prospectively included to evaluate the safety and the effi-
cacy of the Cobra PzF stent. Patients presented with multiple co-morbidities
including 22% DM, 10% AF, 17% EF<40%, 10% VKA, 28% ACS, 10%
STEMI and 26% diffused and multivessel diseases.
Results: 166 Cobra PzF stents were implanted in 151 lesions (74% B1
lesions) via a radial route (72%) with a 6F-guiding catheter. 1.66 stent/pt was
implanted for a mean stent length of 18.7± 0.5mm and a mean diameter of
3.1±0.3mm. Target lesions in left main (2%), LAD Diag (43%), CxMg (23%),
RCA (32%), including bifurcated kissed lesions (12%) were treated with 50%
direct stenting. The device was successfully implanted in 100% of targeted
lesions to achieve a complete revascularization in all cases. In-hospital, there
were no adverse events (Death, MI, TLR, cerebral events, stent thrombosis) or
incidence of major bleeding complications or transfusions. At one month, no
events were reported. 6-month results showed 4% of MACE (terminal cardiac
insufficiency and 3 restenosis successfully treated).
Conclusion: Those Results are very promising in real world and complex
patients (Diabetes, AF, Acute MI, Unstable Angina, Bifurcation, VKA). The
COBRA PzF stent is safe and effective in routine practice. These preliminary
data and the rapid reendothelialization observed in preclinical will serve as an
impetus for a multi-center randomized study of short DAPT.
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Between february 2013 and april 2014, of 1450 coronary angioplaty procé-
dures realized in our institution, 65 patients, aged 64.3 (40-94), underwent
coronary artery stenting with Absorb Biovascular Scaffold (BVS)
Clinical data: exercise angina 22 patients, acute coronary syndromes 37
(including acute myocardial infarction 5), silent ischemia 7, heart failure 2.
Ten patients suffered diabètes (15%) and 14 experienced previous coronay
interventions (20%).
Procedural data: all stents have been implanted under angiographic
control (except two cases including IVUS imaging) in de novo lésions through
a radial approach with 6F guiding catheters following mandatory predilatation.
44 patients had single vessel desease (67%) and 21 multivessel desease.
Target vessel was the left anterior descending artery in 35 cases, left circum-
flex in 10 and right artery in 14. 68 stents have been delivered; three patients
had two BVS; 16 patients had also metallic drug eluting stents in other
arteries. Side branch dilatation had to be performed in 4 patients. Implantation
was successfull in all cases. 
In hospital follow up: No death Complications: side branch occlusion
with non Q wave infarction in one case and transient ischaemic attack in one
another. 58 patients left the institution the day after the procedure under con-
ventionnal dual antiplatelet therapy. 
Out hospital follow up: at 6.2 month (1-15) all patients were event free
(100%) Three patients had angiographic control at one year and were free of
restenosis; one another had 70% angiographic restenosis at the edges of the
stent and underwent longer DES implantation (TLR: 1.5%). Three other
patients had computed tomography scanner control at one year with no evi-
dence of restenosis, including one case demonstrating restoration of systolic
compression of the stented segment in a myocardal bridging whereas diastolic
diameter was normal.
Conclusions: at that time our preliminary data confirm the safety of the
BVS device at implantation and at six months follow up.
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Purpose: This study sought to study the second-generation everolimus-
eluting stent (EES) as compared with first-generation sirolimus-eluting (SES)
in diabetes mellitus (DM) patients.
Methods: All DM patients treated with EES or SES from January 2010, to
December 2011 were included. The EES was compared with SES for the pri-
mary composite endpoint of clinically driven detected restenosis, definite stent
thrombosis (ST), and all-cause mortality.
Results: In 226 percutaneous coronary intervention-treated DM patients,
353 stents were implanted (EES 118, SES 235). The EES was associated with
significantly lower restenosis rates compared with SES (SES vs. EES: 16.7%
vs. 2.8%, p=0,001, OR: 2.96; 95% CI: 1.57 to 5.57). Lower incidence of ST
(SES vs. EES: 2,1% vs 0,8%, p=0,38) and mortality (SES vs. EES: 1,7 % vs
0%, p=0,15) was noted but did not reach statistical significance. 
Conclusions: In all-comer DM patients the use of EES was associated with
improved outcomes compared with SES mainly driven by lower rates of clin-
ically driven detected restenosis.
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Purposes: The aim of this study was to evaluate one-year incidence of
bleeding events and their impact on compliance in patients admitted for ST
Elevation Myocardial Infarction (STEMI) and treated by prasugrel or clopido-
grel in « real-world ». 
Methods: Patients admitted for a STEMI were treated by either clopido-
grel or prasugrel according to the physician with respect of guidelines. The
primary endpoint was the first occurrence of bleeding events within 12 months
assessed by the Bleeding Academic Research Consortium (BARC) classi-
fication using a dedicated questionnaire focused on bleeding events. Topo-
graphy bleedings, causes of premature cessation and ischemic events were
also compared. 
Results: 390 patients were enrolled, 211 in prasugrel group and 179 in
clopidogrel group. Patients in the prasugrel group were younger, with higher
